https://www.selleckchem.com/products/blu-285.html
Lopinavir/ritonavir was also not associated with a reduction of 28-day mortality rate as reported by 1 included study. Most included studies reported gastrointestinal symptoms as side effects from lopinavir/ritonavir therapy. There is not yet enough evidence to support the regular use of lopinavir/ritonavir in the treatment of COVID19. Further clinical trials are needed to evaluate lopinavir/ritonavir's efficacy in treatment. There is not yet enough evidence to support the regular use of lopinavir/ritonavir in the treatment of COVID19.
Like
Comment
Share
